If you have been reading about research chemical and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
== Substrate recognition == Ubiquitin ligases are the final, and potentially the most important determinant of substrate specificity in ubiquitination of proteins. The ligases must simultaneously distinguish their protein substrate from thousands of other proteins in the cell, and from other (ubiquitination-inactive) forms of the same protein. This can be achieved by different mechanisms, most of which involve recognition of degrons: specific short amino acid sequences or chemical motifs on the substrate.
However, this difference is usually neglected most of the time (that is whenever we are not dealing with processes such as sound absorption and attenuation of shock waves, where second viscosity coefficient becomes important) by explicitly assuming
==== Branding ==== Once shaken free of coolant the brand is pressed to the animal's bare skin with a slight rocking motion for between six and sixty seconds, with between 35 and 45 pounds of force (16–20 kg; 170–200 N). Time is most often kept by an assistant with a stopwatch as the difference between a brand that grows back with white hair and one that remains bald forever can be less than five seconds.
==== Pandemic unemployment fraud and debt ==== In January 2021, the Los Angeles Times reported that Newsom's administration had mismanaged $11.4 billion by disbursing unemployment benefits to ineligible claimants, especially those paid through the federally funded Pandemic Unemployment Assistance program. Another $19 billion in claims remained under investigation for fraud. At the same time, legitimate claimants faced lengthy delays in receiving benefits. The state's unemployment system had been overseen by California Labor Secretary Julie Su, a Newsom appointee, whom President Joe Biden later appointed as deputy secretary of labor in February 2021. Political opponents attributed the crisis to the Newsom administration's failure to heed multiple warnings by federal officials of the potential for fraud, while Newsom's administration said the Trump administration's failure to provide appropriate guidance for the new federally funded program contributed to the fraud. Experts said much of the fraud appeared to originate from international criminal gangs in 20 countries. A report by California State Auditor Elaine Howle said $810 million was disbursed to claimants who had fraudulently filed on behalf of inmates in the state's prison system. According to The Sacramento Bee, by the summer of 2021, California owed $23 billion to the federal government for unemployment benefits paid out during the pandemic, which was 43% of all unemployment debt, owed by 13 states at the time, to the federal government.
Sources: en.wikipedia.org
=== Net neutrality === On March 7, 2018, Kennedy introduced a bill that would "prohibit companies like Comcast and Verizon from blocking or throttling web content." He was one of three Republican senators, with Susan Collins and Lisa Murkowski, to vote with the entirety of the Democratic caucus on May 16, 2018, to overturn the FCC's repeal of net neutrality.
== Legacy == Following the dissolution of the Selous Scouts in 1980, most of its white soldiers emigrated to South Africa and were integrated into the South African Special Forces and the South African Police's special units. This formed part of an effort by the SADF to recruit white veterans of Rhodesian counter-insurgency units that was designated Operation Winter. Reid-Daly was among the Selous Scouts who moved to South Africa, and was appointed the head of Transkei Defence Force (the military of the nominally independent 'bantustan' of Transkei) in the early 1980s. He recruited other former Selous Scouts to train the force, but was forced to resign in 1987 after Transkei's rulers were overthrown by a military officer who had previously been trained by the Selous Scouts. The former Selous Scouts contributed to the adoption by the South African security forces of the unit's ruthless tactics. For instance, former Selous Scouts comprised most of the initial personnel of the South African Koevoet unit, and it used similar tactics. This unit was responsible for many human rights violations. The South African Police's Vlakplaas paramilitary hit squad that was established in 1979 was also inspired by the Selous Scouts, as was the Civil Cooperation Bureau that was formed in 1986. Following the end of the Apartheid regime in South Africa some former Selous Scouts joined private military companies. Reid-Daly's memoirs Selous Scouts: Top Secret War, which were first published in 1982, have had a strong influence on the historiography of the Rhodesian Bush War.
== Further reading == Barskov, I. S.; Boiko, M. S.; Konovalova, V. A.; Leonova, T. B.; Nikolaeva, S. V. (2008). "Cephalopods in the marine ecosystems of the Paleozoic". Paleontological Journal. 42 (11): 1167–1284. Bibcode:2008PalJ...42.1167B. doi:10.1134/S0031030108110014. S2CID 83608661. A comprehensive overview of Paleozoic cephalopods. Campbell, Neil A.; Reece, Jane B.; Mitchell, Lawrence G. (1999). Biology, fifth edition. Menlo Park, California: Addison Wesley Longman, Inc. ISBN 978-0-8053-6566-5. Felley, J., Vecchione, M., Roper, C. F. E., Sweeney, M. & Christensen, T., 2001–2003: Current Classification of Recent Cephalopoda. National Museum of Natural History: Department of Systematic Biology: Invertebrate Zoology: Cephalopods Hanlon, Roger; Vecchione, Mike; Allcock, Louise (2018). Octopus, Squid, and Cuttlefish: A Visual, Scientific Guide to the Oceans' Most Advanced Invertebrates. University of Chicago Press. ISBN 978-0-226-45956-1. N. Joan Abbott, Roddy Williamson, Linda Maddock. Cephalopod Neurobiology. Oxford University Press, 1995. ISBN 0-19-854790-0 Marion Nixon & John Z. Young. The brains and lives of Cephalopods. Oxford University Press, 2003. ISBN 0-19-852761-6 Hanlon, Roger T. & John B. Messenger. Cephalopod Behaviour. Cambridge University Press, 1996. ISBN 0-521-42083-0 Martin Stevens & Sami Merilaita. Animal camouflage: mechanisms and function. Cambridge University Press, 2011. ISBN 0-521-19911-5 Rodhouse, P. G.; Nigmatullin, Ch. M. (1996). "Role as Consumers". Philosophical Transactions of the Royal Society B: Biological Sciences. 351 (1343): 1003–1022.
Through a combination of fortune and good political decisions, the Eastern Empire never experienced rebellious barbarian vassals or rule by barbarian warlords—the problems which ensured the downfall of the West. Zeno (r. 474–491) convinced the problematic Ostrogoth king Theodoric to take control of Italy from Odoacer; dying when the empire was at peace, he was succeeded by Anastasius I (r. 491–518). His belief in monophysitism brought occasional issues, but Anastasius was a capable administrator and instituted successful financial reforms including the abolition of the chrysargyron tax. He was the first emperor since Diocletian not to face any serious problems affecting the empire during his reign.
At high pressures, above approximately 10 GPa and temperatures of a few hundred kelvin or less, α-iron changes into another hexagonal close-packed (hcp) structure, which is also known as ε-iron. The higher-temperature γ-phase also changes into ε-iron, but does so at higher pressure. The physical properties of iron at very high pressures and temperatures have been studied extensively because of their relevance to theories about the cores of the Earth and other planets. The Earth's inner core is generally presumed to consist of an iron-nickel alloy with ε (or β) structure. Some controversial experimental evidence exists for a stable β phase at pressures above 50 GPa and temperatures of at least 1500 K. It is supposed to have an orthorhombic or a double hcp structure. (Confusingly, the term "β-iron" is sometimes also used to refer to α-iron above its Curie point, when it changes from being ferromagnetic to paramagnetic, even though its crystal structure has not changed.)
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.